Respiratory Infections Portfolio
Solutions

Respiratory Infections Portfolio

Detection of highly transmissible respiratory pathogens

The BD MAX™️ Portfolio of Respiratory assays

The efficiency and versatility offered by the BD MAX™ System and the Respiratory portfolio facilitate high volume molecular testing for rapid diagnosis and treatment.

Respiratory Infections

Global infection spread

  • Globally, every year there are an estimated 1 billion cases of seasonal influenza, of which 3 to 5 million are severe cases1
  • TB remains the world’s top infectious killer with 10 million contracting the disease each year and 1.5 million deaths4

Global pandemics occur when new strains occur of known respiratory viruses.

  • 2019 novel coronavirus (SARS-CoV-2) is a new strain that has not been previously identified in humans and is an international public health threat

Diagnostic challenges

Diagnosis of acute respiratory infections can be difficult

  • Clinical symptoms: A number of other viruses and bacteria cause similar symptoms so much of influenza-like illness is determined not to be influenza2
  • Management of testing need: Acute respiratory infections spread easily from person to person through the air or by direct or indirect contact. Seasonal or pandemic infection drives high volumes of testing and need for rapid diagnosis to direct isolation and treatment
  • Test result accuracy: Traditional respiratory tests can be less reliable and false positive or false negative results can occur3

Value of molecular testing

Rapid and accurate diagnosis is critical

  • Molecular viral testing with real-time PCR has high sensitivity
  • Molecular testing for TB provides timely results useful for high quality patient care, low contamination risk and ease of performance and speed5
  • Molecular testing is now available for SARS-CoV-2 to efficiently diagnose and inform patient

Meet the BD MAX™ Respiratory Portfolio:

BD MAX™ MDR-TB
  • Mycobacterium tuberculosis complex (MTBC)
  • Rifampin resistance (RIF)
  • Isoniazid resistance (INH)
BD SARS-CoV-2 Reagents
for BD MAX™ System 
  • SARS-CoV-2
CerTest VIASURE 
SARS-CoV-2 Real Time PCR
Detection Kit for BD MAX™ 
  • SARS-CoV-2
CerTest VIASURE
Flu A/B & RSV Real Time PCR
Detection Kit for BD MAX™
  • Influenza A
  • Influenza B
  • Human Respiratory Syncytial Viruses (RSV)

The BD MAX™ System is a single platform capable
of running BD and partner developed assays
as well as laboratory-developed tests

INH, isoniazid; MTBC, Mycobacterium tuberculosis complex; PCR, polymerase chain reaction; RIF, rifampicin; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TB, tuberculosis

1. World Health Organization. 8 Things to know about pandemic influenza. Available at: https://www.who.int/news-room/feature-stories/detail/8-things-to-know-about-pandemic-influenza. Accessed April 2020. 2. European Centre for Disease Prevention and Control. Factsheet about seasonal influenza. Available at: https://www.ecdc.europa.eu/en/seasonal-influenza/facts/factsheet. Accessed April 2020. 3. Centers for Disease Control and Prevention. Information on Rapid Molecular Assays, RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus Infection. Available at: https://www.cdc.gov/flu/professionals/diagnosis/molecular-assays.htm. Accessed April 2020. 4. World Health Organization. Tuberculosis. Available at: https://www.who.int/health-topics/tuberculosis#tab=tab_1. Accessed May 2020. 5. Eddabra R and Ait Benhassou H. Pneumonia. 2018;10:4. Published 2018 May 25.